Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Neurology
Disease Category: Alzheimer's Disease
Trial Information
New Investigational Medication for Alzheimer’s disease
A 52-week, multi-center, randomized, double-blind, placebo-controlled, parallel group study in patients with mild Alzheimer’s disease (AD) to investigate the safety and tolerability of repeated subcutaneous injections of CAD106.
This is a one year placebo-controlled study evaluating SQ injections of a vaccine for patients with mild Alzheimer’s.
Major Inclusion/ Exclusion Criteria:
- Ages 40-85 years inclusive
- MMSE 20-26 inclusive
- More than 2 cerebral micro-hemorrhages on MRI will exclude the patient
Alpine Clinical Research Center
1000 Alpine Avenue, Suite 200
Boulder, CO 80304
Phone: 303-443-7229 ext. 108
EMail: Deb@alpineresearch.com
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
